Agile Therapeutics Says FDA Has Significant Concerns Regarding The Adhesion Of Twirla Which Believes The Co. Cannot Address Through Proposed Patient Compliance Programs; Due To FDA Feedback, The Co. Is Re-Evaluating Plans To Identify Ways To Fund Co. Ops